LONDON – The European Medicines Agency (EMA) has promised to reduce the attrition rate in drug development and start a debate on how new fields such as personalized medicine, nanomedicines and stem cell therapies should be regulated, as part of Road Map To 2015, its strategy for how it will develop its role over the next five years.